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Abstract
Background: It has been shown that a random-effects framework can be used to test the association between a
gene’s expression level and the number of DNA copies of a set of genes. This gene-set modelling framework was later
applied to find associations between mRNA expression and microRNA expression, by defining the gene sets using
target prediction information.
Methods and results: Here, we extend the model introduced by Menezes et al. 2009 to consider the effect of not
just copy number, but also of other molecular profiles such as methylation changes and loss-of-heterozigosity (LOH),
on gene expression levels. We will consider again sets of measurements, to improve robustness of results and increase
the power to find associations. Our approach can be used genome-wide to find associations and yields a test to help
separate true associations from noise.
We apply our method to colon and to breast cancer samples, for which genome-wide copy number, methylation and
gene expression profiles are available. Our findings include interesting gene expression-regulating mechanisms,
which may involve only one of copy number or methylation, or both for the same samples. We even are able to find
effects due to different molecular mechanisms in different samples.
Conclusions: Our method can equally well be applied to cases where other types of molecular (high-dimensional)
data are collected, such as LOH, SNP genotype and microRNA expression data. Computationally efficient, it represents
a flexible and powerful tool to study associations between high-dimensional datasets. The method is freely available
via the SIM BioConductor package.
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Background
The wealth of omics data being currently produced raises
the need for efficient and flexible models to analyse these
data. One typical objective is to understand which molec-
ular changes affect gene expression levels or, if avail-
able, protein expression levels. Molecular profiles reliably
measured currently include DNA methylation and copy
number, sequence information including SNP and loss-of-
heterozigosity (LOH) information, as well as microRNA
expression levels. All these are known to be involved in
gene expression regulation.
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Many methods have so far been proposed for finding
associations between two omics data sets (for an overview
see [1]). These enable us to study for example which copy
number changes affect gene expression levels, or alterna-
tively which methylation changes affect gene expression,
and to which extent they do so. Such findings can for
example shed light onto oncogenicmechanisms. One such
method has been proposed by Menezes et al. [2], whereby
a statistical test is used to for example assess the asso-
ciation between gene expression and the copy number
of a genomic region around it. In that work, the authors
showed the power gain to find associations yielded by
considering sets of measurements, rather than consider-
ing only associations between pairs of features, as done
elsewhere [3].
© 2016 Menezes et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Methods have also been proposed for the joint analysis
of microRNA expression and mRNA expression profiles.
In this context, many microRNAs can target the same
mRNA, and one microRNA can target multiple mRNAs.
So it makes sense to consider target prediction informa-
tion while looking for associations between mRNA and
microRNA expression levels. van Iterson et al. [4] use the
method proposed byMenezes et al. [2], with gene sets now
defined by various target prediction tools. It is then shown
that the method has power to find associations that are
sucessfully validated, in spite of limited sample size. They
also show that predicted associations using sets of fea-
tures lead to more robust, and thus more reliable, results,
in this case with a higher validation rate, than associations
predicted using pairs of features (i.e. one miRNA and one
mRNA at a time). This is in agreement of findings from
Menezes et al. [2]. The extra robustness is brought in by
the fact that the impact on small effects observed for spe-
cific genes must be observed for at least a considerable
subset of genes, before they become significant.
With multiple types of molecular profiles measured, it
makes sense to consider methods for analysing all of them
together. Only a few of the integrated analysis methods so
far proposed have been extended to handling more than
two data sets. Methods proposed byWaaijenborg et al. [5]
and by Witten et al. [6] use a sparse canonical correlation
framework. As such, they are of an exploratory nature,
aiming at finding sets of covariates from the various data
sets which are most correlated.
Here we extend the integrated analysis method pro-
posed by Menezes et al. [2] to handle multiple high-
dimensional data sets. The aim is to test for association
between one type of molecular profile (mRNA, say) and
other types (copy number and methylation, say), the lat-
ter represented by sets of probes, rather than individual
ones. Under the null hypothesis, no association exists
between mRNA and either copy number or methylation,
in our example. The use of sets makes for a robust and
powerful method: robust, because noise originating from
individual probes is ignored; and powerful, because subtle
associations found between mRNA and multiple methy-
lation probes are detectable as the probability of seeing
many of these small associations together by chance will
be considered small, which would be ignored if they were
considered separately. Given the high-dimensionality of
the problem, the fact that our method evaluates statisti-
cal significance is crucial to help separate noise from true
associations. Moreover, since our method uses a regres-
sion framework, it can take confounders into account. As
the original method, it is thus a flexible, powerful and
efficient method to analyse jointly many omics data sets.
This paper is organized as follows. In the “Methods”
section we present the statistical test for associations
between a response and multiple gene sets. Here we will
refer to covariate sets instead of gene sets, essentially
because sets may contain any set of variables, and need
not refer to a gene. In the “Results” section we illustrate
the workings of our method under various types of associ-
ations between data sets with a simulation study. We also
apply our method to sets of TCGA samples: 125 of colon
cancer and 173 of breast cancer, for which copy number,
methylation and gene expression profiles are available.
Methods
The integrated analysis model
Menezes et al. [2] have proposed using score tests to find
associations between a response (say, the expression lev-
els of a gene) and a set of covariates (say, the genomic
copy number measured at multiple loci on the same chro-
mosome arm as the gene). Let us represent by Yni the
expression for gene i, and byXnj the genomic copy number
for gene j, where i = 1, . . . , I and j = 1, . . . , J represent the
sets of probes used, and n = 1, . . . ,N indexes the sample.
Note that it is assumed that measurement sets {Yi}, {Xj}
are available per sample, although it is not necessary that
both sets of probes correspond to the same loci. Then we
write, for any given i,
E (Yni) = h
⎛
⎝α + J∑
j=1
βjXnj
⎞
⎠ , n = 1, . . . ,N , (1)
where h(.) is a given inverse link function and {βj} ∼
N (0, τ), making model (1) a random-effects model. From
now on, we consider observations Yi for a single gene
indexed by i, but we omit the index i for clarity.
The approach proposed by Menezes et al. [2] focuses
not on fitting model (1) directly, but on testing whether or
not the association between Y and {Xj} is statistically sig-
nificant, for each gene expression probe Y. This is done by
making use of the global test [7]. In this framework, under
the null hypothesis that Y is not associated with the set
{Xj}, we have Var(β) = τ = 0. On the other hand, when
Y displays association with variables in {Xj}, then some of
the βj will be non-zero, and thus Var(β) > 0. Specifically,
the global test is a score test for the hypotheses
H0 : Var(β) = 0 vs. Ha : Var(β) = 0,
first proposed by [8] and later applied to the context of
testing association between a molecular profile and a clin-
ical variable by Goeman et al. [7]. Let us define rn =∑
j βjXnj, the part of the linear predictor that depends on
the data, r = (r1, r2, . . . , rN )t , and X an N × J matrix con-
taining all observations for the covariates. Then a statistic
to test the hypotheses above was proposed by Goeman
et al. [7] as
Q(X) ∝ (Y − μ)
tXXt(Y − μ)
(Y − μ)t(Y − μ) , (2)
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or in its standardized form
T = Q(X) − E [Q(X)]√
Var [Q(X)]
. (3)
Applying this test generates one p-value per gene
expression variable Y. For a set of gene expression probes
{Yi, i = 1, . . . , I} a list of I p-values is obtained.
Extension to two sets of covariates
Assume now that a second set of covariates {Zk} is
observed, and there is interest in studying the associa-
tion between both covariate sets and the response Yi. Now
model (1) becomes
E (Yni) = α +
J∑
j=1
βjXnj +
K∑
k=1
γkZnk , n = 1, . . . ,N , (4)
where {βj} ∼ N (0, σ) and {γk} ∼ N (0, τ), so that model
(4) still is a random-effects model, and where we have
assumed for simplicity that h(x) = x. Similarly to the
single covariate-set case, under the null hypothesis no
association exists between either Y and {Xj}, or Y and
{Zk}. In this case, obviously the variances σ , τ of the ran-
dom effects {βj}, {γk} in (4) must be zero. On the other
hand, under the alternative hypothesis, Y displays asso-
ciation with either {Xj} or {Zk}, meaning that either one
of the two random-effect variances σ , τ must be non-
zero. Thus, to test for association between each Yi and
the sets of variables {Xj}, {Zk}, it is of interest to test the
hypotheses
H0 : Var(β) = Var(γ ) = 0 vs.
Ha : Var(β) = 0 or Var(γ ) = 0
To derive the test statistic in this case, we first write the
likelihood for {Yi} as
L(β , γ , σ , τ) = Er
[ I∏
i=1
fi (Yi|ri,β , γ , σ , τ)
]
, (5)
with fi representing the density of Yi, given the random
effect ri = Xiβ+Ziγ , and it is assumed that Cov(β) = σ I,
Cov(γ ) = τ I and Cov(β , γ ) = 0. Using a Taylor series, we
can derive a first-order approximation for the term in the
expectancy as:[ I∏
i=1
fi(0)
]{
1 + 12
I∑
i=1
(σRii + τSii)u2i (0)
+12
I∑
i=1
I∑
j=1
(
σRij + τSij
)
u1i (0)u1j (0)
⎫⎬
⎭ . (6)
Let us define θ = (θ1, θ2) ≡ (σ , τ). By assuming that Yi
has a distribution belonging to the exponential family with
canonical link, we obtain expressions for partial deriva-
tives of the log-likelihood with respect to σ , τ . With some
algebra, we get that the score vector U (θ) is proportional
to
[{Q(R) − tr(RV )} , {Q(S) − tr(SV )}] , (7)
where R ≡ XXt and S ≡ ZZt . From [7] we know that
E[Q(R)]= tr(RV ) and, similarly, E[Q(S)]= tr(SV ). A
detailed derivation is given in Section 2 of the Additional
file 1. Thus, the score vector is formed by the centered and
unscaled individual test statistics, for association between
Y and X,Z separately. It then follows that a test statistic to
test the hypothesis H0 : σ = τ = 0 can be obtained by
using U (θ0)t U (θ0), leading to the expression
[Q(R) − tr(RV )]2 + [Q(Z) − tr(SV )]2 . (8)
Note that this is not the score test statistic, although it
is derived from the score vector. This is similar to the sug-
gestion in Goeman et al. [7] of using only centering while
testing for association with a single set X. For simplicity,
we may ignore the centering and the squaring, then write
the unscaled test statistic for two covariate sets as
Q(X,Z) ≡ Q(X) + Q(Z). (9)
It is interesting to note that, from (2),
Q(X) + Q(Z) = (Y − μ)
t [XXt + ZZt] (Y − μ)
(Y − μ)t(Y − μ) ,
where XXt + ZZt is the matrix in the quadratic form that
would have been obtained if our model had a single set of
covariates given by the merged set {X,Z}, and with effect
modelled by a single vector of random effects. In such
a case, the design matrix would have been obtained by
binding the columns of X and Z together and, thus, the
unscaled score test statistic would be given as above.
The same test statistic (9) could have been derived by
taking σ = η ∗ τ , where η is a given constant, and deriv-
ing the test in terms of τ only. The choice of η is free but
must be made a priori, each choice resulting in a test with
different power properties. It is intuitive to see that this is
possible, and that the derivation used here corresponds to
choosing η = 1, by the equivalence to a test for association
with a single set of covariates.
Thus, a test statistic for two covariate sets can be
obtained as the sum of the individual (centered) test statis-
tics per covariate set, as in (8). Similarly for the unscaled
and unsquared versions of the score test statistics, the test
statistic for two covariate sets X and Z is equivalent to the
one obtained for a single covariate set formed by {X,Z}.
In practice, some sort of centering and scaling of
Q(X),Q(Z) may be used, especially when covariates take
values in different ranges, are of very different sizes and/or
display different variances. In such cases, centering and
scaling can ensure the separate sets are given the correct
weights in the combined test statisticQ(X,Z). This can be
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done by using the scaled individual test statistics as in (8).
An alternative is given in Section 5 of Additional file 1.
Extension to more than two covariate sets
Since the inner product of the score vector is equal to the
sum of the squared and centered test statistics for the indi-
vidual covariate sets, for any given number of covariate
sets M, the test statistic (8) obtained for M = 2 can be
extended for any M. In particular it is straightforward to
show that, if squaring and centering are ignored, the test
statistic for any M number of covariate sets is the same
one as generated by a model with a single covariate set,
formed by merging all covariate sets together.
Data correlation structure
We have seen that the unscaled and linear form of the
test statistic (9) equals the test statistic for a single covari-
ate set, formed by the union of all covariate sets into a
single one, or Q(W ) where W is a matrix formed by the
columns of X,Z bound together. As such, the test statis-
tic proposed considers not only correlation between the
covariates and the dependent variable Y, but also pair-
wise correlations between covariate pairs, as shown by
Goeman et al. [9], section 7. In particular, this means that
the test statistic will have most power in directions where
{X,Z} have the most (co)variance, as well as display asso-
ciation with Y. The specific directions where most power
lies will depend on the correlation structure in the data.
In the “Results” section, we will illustrate in a simula-
tion study how the power varies, considering correlation
structures of practical interest.
Test statistic null distribution
For testing, the distribution of T2XZ under the null hypoth-
esis of no association between Y and X,Z is needed.
Here we will consider the expression (9) for the combined
test statistic. For the single-set testing, Goeman et al.
[10] obtains an expression for the asymptotic distribu-
tion of Q(X) under a generalized linear model, which
is the exact finite sample distribution under the linear
model, as used here. This (asymptotic) null distribution
can be written as a ratio of weighted sums of χ21 random
variables [10].
Our test statistic (9) for two covariate sets X,Z can be
seen as a test statistic for a single covariate set resulting
of the union of the two original sets. This means that the
distributions derived in Goeman et al. [10] can be used
for (9).
Note that, in case of applying the test to many separate
responses {Yi}, such as expression levels of many different
genes, the resulting computational burden of numerically
estimating the distribution per response may be supe-
rior to computing p-values via permutation. In the cancer
examples, we use permutations to compute p-values for
Q(X,Z) for computational ease, and use the sum of test
statistics (9).
Software
Methods presented in this work are implemented in the
Bioconductor package SIM, currently for a single covari-
ate set, and in the short-term for multiple covariate sets.
All computations described and applied in this work
used R from at least version 3.0.1 (see [11] for a recent
reference).
Results
Simulation study
Setup
We run a simulation study to evaluate the power of the
proposed test statistic under various types of effects. A
detailed description of the entire study setup is given in
Section 1 of the Additional file 2. For completeness, here
follows a brief description. The data here is assumed to
consist of two explanatory sets of covariates, {Xj, j =
1, . . . , J} and {Zk , k = 1, . . . ,K}, and a set of dependent
variables {Yi, i = 1, . . . , I}.
We consider four independent data sets, each involving
one set of variables {Yi,Xj,Zk}, with i, j, k = 1, . . . , 1000.
Each data set can be seen as a (genomic) region, here
assumed to involve one association type between the
covariate sets and the dependent variable Yi for i =
1, . . . , 500, and no association for the remaining probes.
The associations considered are: region I, where Yi is
associated with {Xj} only, which we will refer to as “x
only”; region II, “additive”, where both covariate sets affect
outcome linearly; region III, “multiplicative”, where both
covariate sets affect outcome linearly as well as multiplica-
tively; and region IV, “split-samples” or “complementary”,
where {Yi} depends upon {Xj} for half of the samples, and
for the other half {Yi} depends upon {Zk}. For each data
set, three sample sizes are considered: 50, 100 and 200
samples.
Within each region, we test for association between
each Yi and the covariate sets {Xj}, {Zk} using the test
statistic (8). Here p-values are estimated by comparing
the observed test statistic to values obtained after per-
muting the dependent variable samples 1000 times, and
re-computing the test statistics. For the aims of this partic-
ular study, which is to compare ROC curves, no multiple
testing is necessary.
In what follows, we introduce correlation between X
and Z in two different ways. Firstly we define each entry
in Z as a linear function of the corresponding entry in
X, with remaining entries uncorrelated. Subsequently, we
consider a more realistic framework by assigning empiri-
cal correlation structures to X,Z. More details about the
entire study setup are given in Section 1 of the Additional
file 2.
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Z is a function of X
Here we assume that Xj ∼ N (1, 2.25) for all j, with
all Xj independent, and Zk ≡ Xk + Wk , with Wk ∼
N (0, γ ), and Wk⊥Xk , for all k. For simplicity we assume
that I = J = K . The relationship between Xj and
Zk implies that Var(Zk) = Var(Xk) + Var(Wk) and
Cor(Xk ,Zk) = {Var(Xk)/[ Var(Wk) + Var(Xk)] }1/2. The
amount of correlation between Xk and Zk can be changed
by simply changing Var(Wk . For the particular parameter
values chosen here, we would get Cor(Xk ,Zk) = 0.83 if
Var(Wk) = 1 and Cor(Xk ,Zk) = 0.56 if Var(Wk) = 5, for
all k, whilst Cor(Xj,Zk) = 0 for j = k, although observed
values may vary due to randomness.
We will also simulate data with the same assumptions
as above, but now take Zk ≡ −Xk + Wk , so that Xk ,Zk
have a negative correlation. For this case, we will take
Var(Wk) = 1, so that Cor(Xk ,Zk) = −0.83. Note that the
{Xj} are uncorrelated, as are {Zk}, in all three cases.
ROC curves produced for each different type of
effect/region suggest that most power is typically yielded
when the covariate sets X and Z are positive and strongly
correlated (Fig. 1 forN = 100, Additional file 2: Figures S1
and S2 for N = 50, 200). The biggest difference in power
is observed in the situation where X affects the response,
followed by the split-samples case. This is surprising, but
not entirely unexpected. Indeed, in this case Q(Z) brings
information about Q(X) and thus, when their sum is used
for testing, the power to find effects increases the most.
Using empirical correlation structures
In practice, correlation structures can be considerably
more complex than assumed in the previous subsection,
so we here consider two empirical correlation matrices,
derived from the TCGA colon cancer data studied in
the subsection “Colon and breast cancer datasets”. In this
example, gene expression is explained by set of copy num-
ber (CN) or methylation (ME) covariates. Specifically, we
chose genes GGT7 and GDAP1L1, both on 20q. Expres-
sion of both genes was found to be associated with CN
as well as ME in our analyses (see “Examples of effects
found” later on). For GGT7, tests involved 21 CN and 6
ME covariates. Themajority of copy number andmethyla-
tion covariates were negatively associated with each other,
with the strongest Pearson correlation estimated as−0.83.
Gene GDAP1L1 was found to have expression associated
with 20 CN and 2 ME covariates, but here CN and ME
covariates are positively associated with each other, with
Pearson correlation around 0.5. Subsequently, observa-
tions for {Xj} and {Zk} are generated from a multivariate
normal distribution based upon one of the covariance
Fig. 1 ROC curves, simulation study with Z as a function of X. ROC curves to evaluate power to find four different types of effects between one
dependent variable and two independent covariates sets, N = 100. Simulation Study using Z as a function of X. Different line colours correspond to
different amounts of correlation between Z and X
Menezes et al. BMC Bioinformatics  (2016) 17:77 Page 6 of 16
matrices at a time. For both genes, CN measurements are
highly associated with each other (Pearson correlations ≥
0.9 in general).
The ROC curves suggest that power achieved is com-
parable in the two cases, for situations where only one
of the covariate sets is correlated with the response, or
where the covariate sets are correlated to different sub-
sets of observations for the response (Fig. 2, N = 100).
However, when effects are either additive or multiplica-
tive, then power to find effects is greater if the covariate
sets are positively correlated, as is the case withGDAP1L1.
Conclusions remain the same for N = 50, 200 (data not
shown).
We conclude that the test statistic (8) yields acceptable
power to find associations with the response, in situations
of practical interest.
Colon and breast cancer datasets
Data and definitions
In our simulation studies we have shown that the joint
test statistic Q(X,Z) given by (8) can test for, and find,
different types of associations between covariate sets and
responses. Here we will see that its relationship with the
individual test statistics Q(X),Q(Z) can help elucidate the
relative effects of molecular mechanisms under study on
the response. To illustrate this, we will consider molecu-
lar profiling (mRNA, DNA copy number andmethylation)
data for colon (N = 125) and breast (N = 173) can-
cer samples, extracted from The Cancer Genome Atlas
(TCGA). For details about the data, see Section 2.1 of
Additional file 2.
Here we will consider gene expression as the response
variable, and we will study how DNA copy number and
methylation affect expression levels, both individually as
well as jointly. Specifically, we consider a model such as
(4), where Yi represents the ith gene expression probe,
{Xj} represents the set of copy number probes that are
within 1 Mb in either direction of the transcription start
site of the gene, and {Zk} represents the set of methyla-
tion probes that are within 50 Kb of the gene’s transciption
start site in either direction. These window sizes are arbi-
trary and reflect current knowledge on the distance of
cis–regulatory effects of copy number ([3, 12]) andmethy-
lation on gene expression [13].
We computed p-values for Q(X,Z), which we will refer
to as the joint test, as well as for the individual test
statistics Q(X),Q(Z), which will be referred to as the
CN test and the ME test, for association between DNA
Fig. 2 ROC curves, simulation study with empirical correlation matrix for genes GGT7 and GDAP1L1. ROC curves to evaluate power to find four
different types of effects between one dependent variable and two independent covariates sets, N = 100. Simulation Study using an empirical
correlation matrix for X , Z. Different line colours correspond to different correlation matrices, corresponding to the covariate sets for the genes
considered
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copy number or methylation with the gene expression. In
all comparisons, we use p-values not corrected for mul-
tiple testing, as the comparisons between different test
results can be more reliably done in this way (in prac-
tice, multiple testing should always be used). Associations
for which p ≤ 0.001 were selected. In all cases, empir-
ical p-values distributions were verified to be enriched
with small p-values, so that in none of the cases does the
set of mRNA probes selected have small p-values entirely
due to chance. Indeed, if we consider the number of tests
done per chromosome arm (Additional file 2: Table S3),
we can verify that the largest number of p-values that by
chance is smaller than 0.001 is 4, for 1p. Various ratios of
the number of selected tests will be computed, following
definitions in Additional file 2: Table S4
Tables of all mRNA probes tested, with p-values com-
puted by joint and individual tests, can be found in
Additional file 3 for the colon cancer data, and Additional
file 4 for the breast cancer data.
Individual and joint copy number andmethylation effects
Individually, copy number changes explained a larger por-
tion of the gene expression variance than methylation,
notably for the colon cancer data set (see Additional file 2:
Table S5). Interestingly, in the colon cancer data we found
twice as many mRNA expression probes selected as asso-
ciated with copy number (16 % of the total) than in the
breast cancer data (8 %), despite the latter involving almost
50 % more samples than the former (173 and 125, respec-
tively). So, copy number changes seemed to regulate the
expression of a larger number of genes for colon cancer,
compared with breast cancer. The proportion of mRNA
expression probes selected as being regulated by methy-
lation changes was comparable in these two data sets (5.4
and 5.2 % for colon and breast, respectively).
Results separately per chromosome arm mostly reflect
the stronger copy number effect in colon cancer com-
pared with breast cancer. Methylation effects are, on the
other hand, observed in very similar proportions (Fig. 3
and Additional file 2: Table S5 and S6). Examples of this
are found with 1q and 17q. However, two chromosome
arms display more extreme behaviour: 20q and, to a lesser
extent 13q, are outliers in the colon cancer data set, with a
larger proportion of selected associations with either copy
number or methylation than the remaining arms.
Proportions of selected joint tests for colon and breast
cancer (Additional file 2: Figure S3) reflect mostly the pro-
portions found with the CN test (Fig. 3, Left graph); this is
due to the copy number effect largely influencing the joint
effect.
We can better understand these differences if we now
consider test results per gene. For colon cancer, the joint
test yielded virtually the same results as the CN test, for
20q and 13q in colon cancer (see top-left hand-side graphs
of Additional file 2: Figure S4 and S5). In addition, more
than 76 % of all mRNA probes selected by ME tests were
also selected by CN tests (Additional file 2: Figure S6).
As both 13q and 20q often display copy gains in colon
cancer (which is the case in this data), this suggests that
those gains are likely to be important for oncogenesis, and
methylation may be compensating for some of this effect.
In contrast, for breast cancer the joint test selects mRNA
probes that were not selected by the CN test on 20q
(Additional file 2: Figure S4, top-right), and atmost 37 % of
the mRNA probes selected by ME tests were also selected
by CN tests (Additional file 2: Figure S6 and Table S8).
On the other hand, genes on 5q, 16p and 16q dis-
played associationsmostly with copy number, but not with
methylation, for both cancer types (Fig. 3). Here, the joint
test selects additional mRNA probes, not selected by the
Fig. 3 Comparison of copy number and methylation effects. Proportion of genes selected by their expression association with copy number (left)
and with methylation (right), for colon (x-axis) and breast (y-axis) cancers, per chromosome arm
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individual test statistics (see Additional file 2: Figure S7
for 5q – results for 16p and 16q are similar and not
shown). In addition, mRNA probes selected by ME tests
were selected also by the CN test less often (18–35 % in
colon cancer, 52–64 % in breast cancer – Additional file
2: Figure S6). This makes results for 13q and 20q in colon
cancer more remarkable: they yielded the highest percent-
ages of selected CN tests and ME tests, and the largest
overlap of ME tests with CN tests.
Such comparisons help picking up trends that differen-
tiate cancer types, although they obviously ignore region-
specific effects: 17q has commonly amplified regions in
breast cancer with an impact on gene expression [2],
which is not the case for colon cancer.
Overlap between individual and joint tests
Results from joint and individual tests may naturally dis-
play some association: this indicates howmuch of the total
gene expression variability is explained by each individual
effect. Here we considered the proportion of tests selected
both individually as well as with the joint test, compared to
the total of selected joint tests (“CN and joint overlap” and
“ME and joint overlap” , in Additional file 2: Table S4–S7).
When the joint test leads to many extra discoveries com-
pared with the individual test, this proportion is small. If
the proportion is close to 1, however, the joint test statistic
mostly finds associations already identified by the individ-
ual test, suggesting that a single molecular profile drives
effects on gene expression.
The complement of this proportion (obtained by com-
puting 1-proportion), the ratio of new discoveries with the
joint test, points out clearly that large fractions of joint test
new discoveries arise, when compared with the ME test
(Fig. 4). This was expected: most of these result from the
stronger copy number effect. Nevertheless, the advantage
of the joint test is evident as there are new discoveries with
the joint test for all chromosome arms.
The overlap ratios show that, as expected, a relatively
large proportion of mRNA probes selected by joint tests
was also selected by the CN test (80 and 70 % for colon and
breast, respectively — Additional file 2: Table S5). In con-
trast, selected joint tests were also selected with the ME
test at considerably smaller proportions (29 and 41 % for
colon and breast, respectively — Additional file 2: Table
S5). This can be again explained by the stronger copy
number effects in colon cancer, and stronger methylation
effects in breast cancer. Note that herewith when we refer
to a “selected test” we obviously mean a “selected mRNA
probe by the test”.
Results per chromosome arm mostly reflected the
strong copy number effect, especially for colon cancer
(Fig. 5, graphs on top row). Some special patterns appear:
8p and 8q display similar effects in both cancers as 13q
and 20q in colon: selected joint tests were mostly also
selected by the CN test (Additional file 2: Table S6 and S7),
and most selected ME tests corresponded to selected CN
tests (see Additional file 2: Figure S6 for an overview, and
Additional file 2: Figure S8 for 8q).
Another interesting case is 18p, where copy number
changes seemed to drive mRNA expression regulation,
with virtually all (99 %) selected joint tests overlapping
with selected CN tests for colon cancer. For breast can-
cer, selected joint tests corresponded to selected CN and
ME tests in precisely 50 % of the cases each, with no
overlap between selected CN and ME tests (Additional
file 2: Figure S6). Thus, here copy number and methy-
lation changes seem to drive gene expression regulation,
independently of each other, for different genes.
Another interesting example is 19q, for which approx-
imately 63–70 % of the selected joint tests were not
selected by the CN test individually, whilst selected joint
and ME tests had the largest overlap (76–70 %), suggest-
ing that methylation effects may drive gene expression
regulation on 19q, for both cancers. Indeed, methylation
effects dominated the joint test statistic value, although
copy number effects were still found for genes not found
to be associated with methylation change (Additional file
2: Figure S6 and S9).
Methylation seemed to play a stronger role in gene
expression regulation in breast cancer, compared with
colon cancer. This was particularly noticeable examin-
ing the overlap proportions between selected joint and
methylation tests. On chromosome 9, in particular, these
proportions of overlap were strikingly larger in the breast
cancer data (55 and 51 % for 9p and 9q, respectively),
compared with the colon cancer data (23 and 21 % for 9p
and 9q – see Additional file 2: Table S6 and S7). Interest-
ingly, one of the selected genes on 9p is CDKN2A, which
is mapped by six mRNA probes on the Agilent expression
microarray used. Of these, two were selected as associated
with both the methylation and the joint tests in the breast
cancer data, and two were just above the selection thresh-
old (p-values ≤ 0.005) with these two tests. In contrast, in
the colon cancer data only one probe would be selected
with a less stringent cut-off, by the methylation and the
joint tests (p ≤ 0.005). Indeed, methylation and gene
expression were associated in both data sets, although
the correlation was more widely and evenly spread
across both methylation as mRNA-expression probes
(Additional file 2: Figure S10).
In order to better understand the mechanisms regu-
lating CDKN2A expression, let us consider the mRNA
probe A_23_P17356 which had significant associations
in breast, but not colon, cancer. A total of 49 breast
cancer samples displayed DNA copy loss, whilst only 6
colon cancer samples displayed a small loss in this region
(Additional file 2: Figure S11–S12, top). Note that the
mRNA probe was often not under-expressed for these
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Fig. 4 Joint test new discoveries. Computed as the proportion of genes with selected expression association with the joint set of covariates, that
was found not to be selected by either copy number (left-hand side, blue shades) or methylation (right-hand side, purple shades) separately. Top:
colon cancer. Bottom: breast cancer
samples. After sorting samples in the methylation data
according to the copy number data heatmaps, we see that
the samples displaying larger DNA copy loss (right-hand
side) also displayed hypo-methylation of about half of the
probes which, again, was only observed for breast can-
cer (Additional file 2: Figure S11–S12, bottom). We then
looked at scatterplots of A_23_P17356 expression and
the 19 methylation probes in the covariate set tests, which
suggested that many of those displayed negative associ-
ation with mRNA expression in breast cancer, but not
in colon, as expected of a functional hyper-methylation
event affecting gene expression (Additional file 2: Figure
S13–S14). In particular, DNA loss was associated with
hypo-methylation of some probes in breast cancer, but
these probes were not correlated with mRNA expres-
sion. Indeed, methylation probes correlated with mRNA
expression did not show correlation with DNA copy num-
ber. This suggests that, in breast cancer, methylation
affects CDKN2A expression, independently of DNA copy
number change.
Tests with different conclusions
A selected joint test typically corresponded to at least one
selected individual test, making interpretation of results
straightforward. However, there was a small but non-
negligible proportion of mRNA probes (0.6 % for colon
and 1.2 % for breast) that was selected by the joint test,
whilst that was not the case with either of the individual
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Fig. 5 Comparing individual and joint tests: overlap and dilution. Top row: overlap between individual and joint tests. Computed as the proportion
of genes selected by both its expression being associated with the joint set of covariates, formed by both copy number and expression, as well as by
each single set of covariates, per chromosome arm. This proportion is relative to all selected joint tests. Bottom row: dilution. Computed as the
proportion of selected genes for expression association with one set of covariates (either copy number or methylation), that are not selected with
the joint set of covariates, formed by both copy number and expression, per chromosome arm. The proportion is relative to all selected tests for
association with either copy number (bottom-left) or methylation (bottom-right)
tests (see line “Joint sel but not CN ME/joint sel” in
Additional file 2: Table S4–S5). Such cases tended to
reflect small effects spread across multiple covariates,
in this case both copy number and methylation probes,
with the collection of small effects leading to an associa-
tion with the larger covariate set being selected. As such,
these are worthy of further investigation. Looking at the
results per chromosome arm, we found that 11p and 17p
had relatively high proportions (4 and 3 % respectively)
of effects found only with the joint test statistic, for the
breast cancer data (see Additional file 2: Figure S15 and
Table S7).
There were also mRNA probes selected only by an indi-
vidual test, but not by the joint test. Indeed, around 21% of
the mRNA probes selected by CN tests were not selected
by the joint test, for both colon and breast cancers. If
such effect dilution occurs, the conclusion is obviously
that copy number affects gene expression whilst methyla-
tion does not, to an extent that the copy number effect,
either not very strong or only spanning a small subset of
the copy number variables, is no longer enough to drive
the result of the joint test statistic. From themRNAprobes
selected byME tests, between 15 and 27 % were found not
to be selected by the joint test, for colon and breast cancer
respectively.
Copy number effects were found to be up to 40 %
diluted for most arms (Fig. 5, bottom-left). This was partly
expected due to the large overlap between joint and CN
tests. On exception is 19q, of all mRNA probes selected
by the CN test, around 57 % for colon and 43 % for breast
were not selected by the joint test statistic, whilst for the
ME test these proportions were 1 and 8 % respectively
(Fig. 5, bottom-right). So, 19q is a chromosome armwhere
methylation effects dominated the joint test statistic and,
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as such, were diluted to a very small extent; on the other
hand, about half of the individual copy number effects
were diluted in the joint test statistic.
Overall, we observed more dilution of methylation
effects in the joint test statistic with the breast cancer data,
compared with colon (bottom-right hand-side graph in
Fig. 5). This is likely due to the fact that the breast cancer
displayed more methylation effects but, as these effects
were mild, they were more likely to be diluted in the joint
test statistic. The largest methylation-effect dilutions in
the breast cancer data were observed for 6q, 7p, 8p and 8q,
where the last two yielded at least 92 % of selected joint
tests also being selected by the CN test, for both colon
and breast cancer. What the dilution proportions tell us is
that the copy number effect dominance comes at the cost
of the methylation effect: between 18 and 31 % in colon
cancer, and between 53 and 71 % in breast cancer, of the
methylation effect was “lost”. This is also evident from the
gene-wise test graphs for these chromosome arms, as a set
of p-values that is near zero for the ME test, but not for
CN or joint tests (Additional file 2: Figure S8 and S16 for
8q and 6q, respectively).
Examples of effects found
Our results highlight a variety of effects of copy number
and methylation explaining gene expression variability. To
illustrate this, we selected probes found with our tests and
examined corresponding patterns in the data motivating
the findings. For each test, we selected probes for which
a test had p-value ≤ 0.001. Specific criteria used to select
mRNA probes for detailed analysis are given in subsection
“Examples of genes found: selection criteria” of Additional
file 2.
The selection criteria used are likely to find mRNA
probes with strong copy number effects on 13q, 20q and
8q, as we know these characterize the colon cancer data.
Indeed, this is what we found, but with an interesting
twist: copy number seemed to explain mRNA expression
for only part of the samples, with in almost all cases a sub-
set of samples with diploid copy number and yet varying
mRNA expression. This was the case with genes GGT7,
PIGU, NUFIP1, WFDC2, SLC39A4, PCDH20 and IFT52
(Fig. 6 and Additional file 2: Figure S17 and S22). Since
these probes were also selected on the basis of theME test,
we expected methylation to also regulate mRNA expres-
sion, in particular in diploid samples, in spite of the strong
copy number effect. Indeed, we found that, not only sam-
ples with DNA copy gain also have less methylation, but
also diploid samples more often displaymoremethylation.
For these samples, it seems that copy number and methy-
lation have an additive effect on mRNA expression. Note,
however, that in most cases, copy number and methyla-
tion did not explain mRNA expression completely, with
a few samples displaying less methylation as well as a
copy gain, and yet being under-expressed compared to the
remaining samples. This suggests that a third mechanism
is regulating mRNA expression for a subset of samples, for
example down-regulating mRNA expression in samples
with DNA copy gain and less than average methylation,
or up-regulating mRNA expression in diploid samples
with more than average methylation. In such cases, the
event of up- or down-regulation of mRNA expression is
thus achieved by different mechanisms depending on the
sample, which illustrates the concept of complementary
effects introduced in the simulation study.
It is interesting to note that themRNA regulatory mech-
anism just described implies that DNA copy number and
methylation are negatively correlated. This is the opposite
from what we expect if a copy number change occurs at
random, which would alter methylation in the same direc-
tion. This suggests again that the methylation changes
are functional, since they neither can be a consequence
of DNA copy gain nor are they likely to have occurred
by chance (and thus not be functional) on the diploid
samples.
Not all probes followed this pattern. Probe
A_23_P17356, mapping to gene GDAP1L1, is interest-
ing because copy number also separated samples into
diploid and copy gain, but now copy gain samples are
under-expressed compared with diploid ones (Fig. 7).
Methylation still displayed a (negative) association with
gene expression, for at least two probes. It is possible that
methylation compensated for the DNA copy gain here,
since 20q is very often gained in colon cancer.
Finally, the probe selected on 19q on the basis of the ME
and joint tests, mapping to the SLC7A9, showed indeed
methylation negatively correlated with mRNA expression
(Additional file 2: Figure S23). As expected, DNA copy
number was not correlated with mRNA expression.
The probe chosen mapping to CDKN2A displays a
similar pattern to that for SLC7A9, with a trend of
over-expression for samples displaying more methyla-
tion by one or both methylation probes. On the other
hand, almost all samples with under-expression displayed
more methylation with at least one of the two methyla-
tion probes (Additional file 2: Figure S24). This was not
observed for the same probe in breast cancer samples.
We conclude that expression of CDKN2A is often regu-
lated via methylation, but that this can be best represented
by different mRNA probes, for breast and colon can-
cer. Methylation probes showing strong association with
mRNA expression may be the same, as is here the case.
After observing that methylation plays an important
role in gene-expression regulation in breast cancer, we
also looked for genes that had, for the ME test, p ≤ 0.001
and p > 0.1 in breast and colon cancer, respectively. This
yielded 439 genes. In order to make the selection even
stricter, we required that each gene had at least twomRNA
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Fig. 6 Gene GGT7: expression, methylation and copy number. mRNA expression (y-axis) of one probe mapping to gene GGT7 in the colon cancer
data. Top graphs: methylation values (logit of beta values) for chosen probes within 50 Kb of the gene start site; point colours represent the
dychotomized copy number (see legend and dashed line in the graph right below), with blue corresponding to approximately diploid number of
copies; the vertical dashed line represents the cut-off used to separate samples with more or less methylation.Middle graphs: median copy number
values across all measurements within the 1 Mb region around the gene start site; point colours represent the dychotomized methylation (see
legend and dashed line in the graph right above), with blue corresponding to less methylation; the vertical dashed line represents the cut-off used
to separate samples approximately diploid from those. Bottom graph: mRNA expression for all samples, sorted from the smallest to the largest; three
plotting symbols are used per sample to convey dychotomized copy number (star), methylation probe 1 (upwards triangle) and methylation probe
2 (downwards triangle); symbol colours are blue for lower values (diploid copy number, less methylation) or pink (copy gain, more methylation), as
before
probes satisfying the criterion, which led to 274 genes.
This list included geneMGC29506, also known asMZB1.
It has been previously found to be frequently methylated
in hepatocellular cancer [14]. Of the 4mRNAprobesmap-
ping to it, two aremethylated above average for all samples
(data not shown). Another gene on this list is RAB40C,
a member of the RAS oncogene family. Of the 6 mRNA
probes mapping to it, 2 are significant and exhibit a nega-
tive correlation betweenmedian copy number and mRNA
expression (data not shown).
The above mechanisms illustrate effect types that can
be found by our approach, squeezing relevant information
out from thousands of mRNA probes, copy number and
methylation measurements and yielding a list of mRNAs
for further investigation. Obviously, correlation does not
mean causation: further research would be needed to ver-
ify which of the associations found indeed is functional.
In particular, statistical significance need not lead to bio-
logical relevance: as with any statistical method, there are
effects found of too small a magnitude to be biologically
relevant.
Discussion
We have proposed a test to find associations between
a dependent variable and two or more sets of covari-
ates. It can be used for example to test for associ-
ations between a gene’s expression levels with copy
number and/or methylation in a region around it.
These help us better understand molecular mecha-
nisms of gene expression regulation, individually and
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Fig. 7 Gene GDAP1L1: expression, methylation and copy number. mRNA expression (y-axis) of one probe mapping to gene GDAP1L1 in the colon
cancer data. Top graphs: methylation values (logit of beta values) for chosen probes within 50Kb of the gene start site; point colours represent the
dychotomized copy number (see legend and dashed line in the graph right below), with blue corresponding to approximately diploid number of
copies; the vertical dashed line represents the cut-off used to separate samples with more or less methylation.Middle graphs: median copy number
values across all measurements within the 1 Mb region around the gene start site; point colours represent the dychotomized methylation (see
legend and dashed line in the graph right above), with blue corresponding to less methylation; the vertical dashed line represents the cut-off used
to separate samples approximately diploid from those. Bottom graph: mRNA expression for all samples, sorted from the smallest to the largest; three
plotting symbols are used per sample to convey dychotomized copy number (star), methylation probe 1 (upwards triangle) and methylation probe
2 (downwards triangle); symbol colours are blue for lower values (diploid copy number, less methylation) or pink (copy gain, more methylation), as
before
jointly, as we showed with the colon and breast cancer
TCGA data.
In our illustrations, we have not corrected for multi-
ple testing, even though many hypotheses were tested
simultaneously. This was done for the sake of clarity:
our illustrations involved comparing results from differ-
ent data sets, and such comparisons are better made on
the basis of uncorrected p-values. Indeed, multiple testing
correction such as FDR may for example yield the same
corrected p-value for many hypotheses, and it often does,
even if uncorrected p-values are distinct. In practice, obvi-
ously multiple testing correction must be used if the test
is applied many times.
Other methods have been proposed to look for associ-
ations between one molecular profile, and two or more
other profiles. One framework that has been used by var-
ious authors for the two-dataset case (one independent)
and, by some, has been extended to the three-dataset
case, is that of penalized canonical correlations [5, 6, 15].
This framework tries to find (linear) combinations of
the variables in the molecular profiles datasets that
are (most) strongly correlated. As such, they are of an
exploratory nature. Indeed, canonical vectors essentially
identify sets of variables that are most strongly corre-
lated. While their correlation may be considered high,
it could still be due to chance, especially considering
the high-dimensionality and sparseness of the data sets.
In addition, due to their very nature sparse-canonical
correlation-based approaches are computationally com-
plex, and the complexity increases very quickly with each
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added independent dataset, as well illustrated by Lee et al.
[15]. Compounded with the high-dimensions of the
datasets involved, this means that such methods do not
easily scale up. Furthermore, it can be difficult to interpret
the canonical vectors.
In contrast, our approach is meant to be used when
researchers have given sets of interest, which is is often
the case in practice. Here we studied gene expression-
regulating mechanisms by copy number and methylation,
and used sets of measurements is cis, in and around
the gene are of interest. We could have also considered
trans effects by simply expanding the set. To study gene
expression-regulating mechanisms by microRNA expres-
sion, one could form a set of microRNA (families) that
may target that gene. To study eQTLs affecting a gene’s
expression, natural sets are all SNPs in haploblocks map-
ping to a 2 Mb region centered around the start of the
gene [16]. Our approach then tests the association of the
dependent variable with all covariates in the set.
Bayesian approaches have also been proposed to analyse
two datasets (one independent) together [17–19], but as
such approaches are naturally computationally complex,
they often become prohibitively computationally com-
plex when used on the whole genome, or for more than
one independent data set. Richardson et al. [18] tried to
address the complexity by proposing amore efficient algo-
rithm for MCMC estimation, although they do not apply
their method to more than two data sets in their paper.
Our approach is computationally simple, so it can be
scaled up to the whole genome and be used with many
covariate sets. The simplicity results from the focus on
testing, rather than on model fitting, as do Bayesian
approaches, or on finding canonical vectors. This allows
for quick, simple and objective evaluation of results, and
easy prioritization of found associations.
Vaske et al. [20] proposed another method to analyse
multiple molecular profiles simultaneously. Their method
first replaces multiple probes by pathways, producing a
matrix of inferred associations between samples and path-
ways, which is used, instead of the entire dataset, in anal-
yses. This data with reduced dimensions is then used to
build directed graphs. This process involves discretization
of the data set, to enable establishment of direction in the
graph estimation. As such, it relies on pathways contain-
ing information relevant to the study, as well as biological
information about molecular interactions within path-
ways. This makes for a much more structured method,
that is of particular interest when specific pathways and/or
processes are under study. Indeed, results are reported per
pathway, so relating them back to the genes is not trivial.
Our method is less structured, and this enables us to
find a wide variety of types of association between covari-
ates and the response which, as we saw in the TCGA data
example, may not be linked to any known pathway. So it
is preferred in cases where no particular effect is a priori
of interest. The lack of imposed structure makes it more
flexible. Indeed, our approach could be used on the matrix
of inferred pathway activities generated by the approach
of Vaske et al. [20], instead of their proposed graphical
model, where we would have ignored the interaction fac-
tors. Here all pathways could be used in a single set of
covariates to study relationship with a clinical outcome,
for example. In particular, results are easy to interpret:
not only it indicates clearly if the response is associated
with the covariates, but also we can decompose each test
statistic into the separate contributions of each covariate
towards the joint set, pinpointing covariates driving the
test result [7].
In the TCGA data examples, we observed similarities
and differences between how copy number and methyla-
tion regulate gene expression in these two cancer types.
For some chromosome arms, such as 1q and 17q, propor-
tions of discoveries are similar between the two cancers.
This needs not mean that the same gene expression-
regulating mechanisms are involved, but that genomic
changes of the same type are involved at the same ratio.
Also, copy number and methylation do not necessarily
explain gene expression variation of the same genes, and
the joint test finds additional associations compared to the
individual tests. For other arms, such as 13q and 20q, there
are clear differences between the genomic changes found
to affect gene expression in colon and breast cancer.
Some genes were selected to illustrate patterns found
by the method, which showed some expression-regulating
mechanisms driven by a combination of copy number and
methylation changes. This is just the tip of the iceberg,
with many other potentially interesting effects contained
in the results. Researchers interested in further explor-
ing our results can use the whole-genome results table
provided (Additional files 3 and 4).
The pioneering articles of TCGA colon [21] and breast
[22] cancer samples characterization have of course
already given a detailed overview of molecular changes
observed in these data sets. They have, however, not
looked for complex regulatory mechanisms as we do here.
So, our findings complement theirs, although we must
be careful when extending the results from the samples
subset used here to a larger set of cancer samples, as we
cannot guarantee that the samples we chose represent well
all similar cancer samples.
In the illustrations above we assumed that gene expres-
sion was the molecular phenotype of interest. Clearly
that is not always the case, and other molecular pheno-
types of interest include protein expression profiles. Our
method can equally well be applied to such cases, with
the reason for us not to have done so is the relatively lim-
ited number of samples with protein profiles available. In
our experience, a minimum number of samples needed
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to yield reliable results is about 20 for the two-dataset
case (one independent), but that of course is very much
dependent on the signal-to-noise ratio in the data sets.
Our approach can also be used in a generalized-linear
model context, where the dependent variables are related
to the sets of covariates via a link function, such as the log-
arithm or the logit. This extension is straightforward, as
we use the framework of the global test [7, 9]. This allows
us for example to consider RNA-Seq data as dependent
variables, if a suitable data transformation exists such that
covariate effects can represent well variability in the trans-
formed RNA-Seq data. Ideally, we would like to represent
the data variability using the negative binomial, as done
for example by the BioConductor packages edgeR ([23])
and DESeq ([24]), as it handles the data overdispersion
([25]). Note, however, that this is not straightforward as
the negative binomial distribution is not in the exponen-
tial family. This extension is beyond the objectives of this
paper and will appear elsewhere.
Another application of interest is to study the impact
of changes in multiple molecular profiles on patients’ sur-
vival outcome, a variable formed by time from diagnosis to
event and event information. This can be done by means
of a Cox proportional-hazards model as an extension of
the global test for this setting proposed earlier [26].
Conclusions
We propose a method to find complex associations
between multiple covariate sets, for example molecular
profiles, and a response, which can be a single clinical
variable or part of a molecular profile. Computation-
ally efficient and flexible, our method can help unravel
complex gene expression-regulating mechanisms.
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